Loading
A phase 2 trial of Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and Polatuzumab vedotin in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) is a phase 2 interventional study registered as NCT06890884 by Merck Sharp & Dohme LLC, with 594 participants planned, started 2025-04-11 and due to reach its primary completion in 2027-12-13. Interventions recorded: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar and Prednisone.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin.
Shares Prednisone, Rituximab, Doxorubicin, Monoclonal antibodies and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Doxorubicin, Cyclophosphamide, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/